Saturday, December 4, 2021  | 28 Rabiulakhir, 1443
Samaa TV
Facebook Twitter Youtube
HOME > Health

US trial for Moderna’s coronavirus variant vaccine begins in March

FDA says variant vaccines won't go through lengthy clinical testing

SAMAA | - Posted: Feb 27, 2021 | Last Updated: 9 months ago
SAMAA |
Posted: Feb 27, 2021 | Last Updated: 9 months ago

Photo: AFP

Listen to the story
The US will begin in mid-March a clinical trial of a version of Moderna's Covid vaccine specific to the South Africa variant, Dr Anthony Fauci, the top advisor to the White House on the pandemic, said Friday.  The Phase 1 trial will involve 210 people to study both the immune response generated by the vaccine and its safety, he said. Unlike previous trials there will be no placebo, and instead the experiment will look at various combinations of the new vaccine and the old, both in people who were previously vaccinated and in people who have never before been vaccinated.  The goal is to determine how well the different strategies compare in their ability to neutralize the B.1.351 strain, which has been shown to partly reduce the effectiveness of the current generation of vaccines. Carrying out the early-stage trial "does not necessarily mean a commitment to make 300 million, or 600, million doses of this vaccine," said Fauci.  "This is all going to depend on the dynamics of the outbreak and what other variants might be dominant." The Food and Drug Administration said earlier this week that variant-specific Covid vaccines would likely not need to go through the same level of clinical testing that the first versions did before they receive authorization.
FaceBook WhatsApp

The US will begin in mid-March a clinical trial of a version of Moderna’s Covid vaccine specific to the South Africa variant, Dr Anthony Fauci, the top advisor to the White House on the pandemic, said Friday. 

The Phase 1 trial will involve 210 people to study both the immune response generated by the vaccine and its safety, he said.

Unlike previous trials there will be no placebo, and instead the experiment will look at various combinations of the new vaccine and the old, both in people who were previously vaccinated and in people who have never before been vaccinated. 

The goal is to determine how well the different strategies compare in their ability to neutralize the B.1.351 strain, which has been shown to partly reduce the effectiveness of the current generation of vaccines.

Carrying out the early-stage trial “does not necessarily mean a commitment to make 300 million, or 600, million doses of this vaccine,” said Fauci. 

“This is all going to depend on the dynamics of the outbreak and what other variants might be dominant.”

The Food and Drug Administration said earlier this week that variant-specific Covid vaccines would likely not need to go through the same level of clinical testing that the first versions did before they receive authorization.

 
HOME  
 
 
RELATED STORIES

Tell us what you think:

Your email address will not be published.

FaceBook WhatsApp
 
 
 
 

MOST READ
MOST READ
Karachi’s first winter spell to hit after December 6
NAB arrests Sindh Assembly speaker Agha Siraj Durrani
Pakistan Embassy Serbia’s Twitter ‘hacked from Karachi’
Philippine national found dead on ship at Port Qasim
Imran wants PAC to expose his government’s corruption as well
PM, COAS condemn Sialkot lynching as Sri Lanka demands probe
Islamabad bound flight survives bird strike
President Alvi signs EVMs bill into law
 
 
 
 
 
About Us   |   Anchor Profiles   |   Online Advertising   |   Contact Us   |   Feedback   |   Apps   |   FAQs   |   Authors   |   Comment Policy
Facebook   |   Twitter   |   Instagram   |   YouTube   |   WhatsApp